We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ASRT
1951
DELISTED
Assertio
ASRT
| $2.98K | ﹤0.01% |
37
-9
| -20% | -$836 |
|
1952
Barclays
BCS
$85B
| $2.93K | ﹤0.01% |
373
| – | – |
|
1953
Ocugen
OCGN
$335M
| $2.92K | ﹤0.01% |
+5,374
| New | +$3.45K |
|
|
CSGS
1954
DELISTED
CSG Systems International
CSGS
| $2.9K | ﹤0.01% |
55
-967
| -95% | -$49.4K |
|
1955
Embecta
EMBC
$287M
| $2.87K | ﹤0.01% |
+133
| New | +$3.63K |
|
1956
ING
ING
$105B
| $2.87K | ﹤0.01% |
213
| – | – |
|
1957
Forward Air
FWRD
$562M
| $2.87K | ﹤0.01% |
27
-24
| -47% | -$2.46K |
|
|
STRR
1958
Star Equity Holdings
STRR
$36.2M
| $2.84K | ﹤0.01% |
132
+52
| +65% | +$1.1K |
|
1959
Genie Energy
GNE
$418M
| $2.8K | ﹤0.01% |
198
+48
| +32% | +$711 |
|
|
RAD
1960
DELISTED
Rite Aid Corporation
RAD
| $2.79K | ﹤0.01% |
1,846
+1,545
| +513% | +$3.09K |
|
1961
Evolv Technologies
EVLV
$920M
| $2.78K | ﹤0.01% |
+463
| New | +$2.19K |
|
1962
a.k.a. Brands
AKA
$119M
| $2.78K | ﹤0.01% |
538
+225
| +72% | +$1.1K |
|
1963
Shutterstock
SSTK
$183M
| $2.77K | ﹤0.01% |
57
-238
| -81% | -$13.6K |
|
1964
Edgewise Therapeutics
EWTX
$4.73B
| $2.77K | ﹤0.01% |
357
-8,746
| -96% | -$73.8K |
|
1965
ArcelorMittal
MT
$55.3B
| $2.73K | ﹤0.01% |
+100
| New | +$2.75K |
|
1966
Hudbay
HBM
$11.2B
| $2.73K | ﹤0.01% |
570
| – | – |
|
|
EGIO
1967
DELISTED
Edgio, Inc. Common Stock
EGIO
| $2.72K | ﹤0.01% |
101
+82
| +432% | +$1.94K |
|
1968
Nerdy
NRDY
$76.1M
| $2.7K | ﹤0.01% |
+43
| New | +$2.29K |
|
1969
National Health Investors
NHI
$3.42B
| $2.67K | ﹤0.01% |
51
-112
| -69% | -$5.77K |
|
1970
Alaska Air
ALK
$4.45B
| $2.61K | ﹤0.01% |
49
-50,015
| -100% | -$2.27M |
|
1971
Teekay Tankers
TNK
$3.46B
| $2.6K | ﹤0.01% |
68
+47
| +224% | +$1.83K |
|
1972
News Corp Class B
NWS
$18.1B
| $2.44K | ﹤0.01% |
124
+35
| +39% | +$640 |
|
1973
CytomX Therapeutics
CTMX
$608M
| $2.43K | ﹤0.01% |
1,415
| – | – |
|
|
TRUE
1974
DELISTED
TrueCar
TRUE
| $2.43K | ﹤0.01% |
1,074
| – | – |
|
|
SURF
1975
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $2.29K | ﹤0.01% |
2,638
| – | – |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.